Neumora Therapeutics’ KOASTAL-1 study of navacaprant for MDD falls short on primary endpoint

Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company specialising in neuroscience, has announced results from the KOASTAL-1 Phase 3 study evaluating navacaprant as a ... Read More